Molecular Biotechnology - Bernard R. Glick
ll4.me Molecular Biotechnology - Bernard R. Glick Acclaimed by students and instructors, Molecular Biotechnology is now in its fourth edition, bringing it thoroughly up to date with the latest findings and the latest industrial, agricultural, pharmaceutical, and biomedical applications. At the same time, the text maintains all the hallmarks that have made it a bestseller. These include its straightforward, jargon-free writing style and its extensive use of figures that help students make sense of complex biological systems and processes.Author: Glick, Bernard R. Publisher: ASM Press Illustration: N Language: ENG Title: Molecular Biotechnology Pages: 01018 (Encrypted PDF) On Sale: 2011-03-16 SKU-13/ISBN: 9781555814984 Category: Science : Life Sciences - Microbiology Acclaimed by students and instructors, Molecular Biotechnology is now in its fourth edition, bringing it thoroughly up to date with the latest findings and the latest industrial, agricultural, pharmac bernard r. glick, science, life sciences, microbiologyFrom:candacechamblee324Views:0 0ratingsTime:00:10More inPeople Blogs

Read the rest here:
Molecular Biotechnology - Bernard R. Glick - Video

Recommendation and review posted by G. Smith

Til I forget my name
soundcloud.com ...Akkhail woke up and the future, utopia or dystopia...was there, vast horizons of blue skies on controlled expansions of integrated technology, seamless with nature. It was obvious that nanorobots were purifying the air, while the bioengineered plants were repairing two centuries of damages to the planet. The entire landscape was the result of robotics applied to nano and biotechnology. What was missing were humans. It was only after many hours of exploration that the first man appeared on a chair, in the patio of a beautiful villa integrated with the landscape: the sun and blue skies reflected n his virtual glasses, while a cable was connected to what obviously was the chip in his brain: he was immersed into a different world, a virtual one where he was just software, his consciousness merged with billion of other consciousness, in a network of souls that interacted at a level never reached by the stimuli of Akkhail #39;s time...From:Bugbe4rvirusViews:0 0ratingsTime:04:17More inMusic

More here:
Til I forget my name - Video

Recommendation and review posted by G. Smith

Genetics-Iran-11-04-2012
DesiGirlsNetwork.Blogspot.com http Updates World News Plz Subscrib for Latest World News Iranian scientists have been working in the field of genetics for half of a century. Today the institute of genetic engineering and biotechnology is one of the leading research centers in the region. Its activities are aimed at enhancing the quality of life by better food medicine and environment. Amir Mehdi Kazemi reports on genetic engineering and biotechnology in Iran. Follow our Facebook on: http://www.facebook.com Follow our Twitter on: twitter.comFrom:UpdatesWorldNewsViews:0 0ratingsTime:06:41More inNews Politics

Go here to see the original:
Genetics-Iran-11-04-2012 - Video

Recommendation and review posted by G. Smith

ZURICH, Nov. 6, 2012 /PRNewswire/ --Cytos Biotechnology Ltd ("Cytos" or the "Company") announced today financial results and business highlights for the quarter ended September 30, 2012.

Highlights

Cytos completed its restructuring during the third quarter 2012 with the appointment of Dr.Christian Itin as Chief Executive Officer in October, taking office on November 5, 2012. Dr. Itin is also proposed to be elected to the Board of Directors and to chair the Board of Directors upon election at an Extraordinary Shareholders' Meeting to take place on November 20, 2012. Dr. Thomas Hecht and Mr. Jakob Schlapbach will step down from the Cytos Board at this meeting.

During the period, the Company also made good progress in preparing the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma which is expected to start in the fourth quarter. This important trial is aiming to recruit approximately 360 adult patients suffering from moderate to severe allergic asthma not sufficiently controlled on current standard therapy. The study is expected to be conducted at more than 90 centres in North America and Europe, and to read out top-line data in 2014.

Dr. Itin (age 48 yrs.) is the former President and Chief Executive Officer of Micromet Inc., a previously Nasdaq-listed biopharmaceutical company, with headquarters in the USA and a R&D center in Germany. Dr. Itin led Micromet as CEO from 2004 until its acquisition by Amgen for $1.2 billion in cash in March 2012. In total he spent 13 years in senior management roles at Micromet. Prior to joining Micromet in 1999, Dr. Itin co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA.

Dr. Itin was awarded a degree in biology and a Ph.D. in cell biology from the University of Basel. In addition, he has undertaken post-doctoral research at the Biocenter of Basel University and at the Stanford University School of Medicine.

The detailed Q3 Financial Report can be downloaded at http://www.cytos.com/userfiles/file/Cytos_Q3_2012_E.pdf

For further information please contact:

About Cytos Biotechnology Ltd Cytos Biotechnology Ltd is a Swiss public biotechnology company focused on the development of its lead product candidate CYT003 in allergic asthma. CYT003 has successfully completed a phase 2a trial in patients with persistent allergic asthma receiving standard inhaled corticosteroid (ICS) treatment, where it was shown to maintain lung function and asthma control as ICS treatment was withdrawn. CYT003 acts via a novel mechanism of action: it targets the Toll-like receptor 9 (TLR-9) pathway, which inhibits the immune response that leads to the allergic asthma response. Cytos plans to initiate Phase 2b studies with CYT003 in allergic asthma patients in 2012.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich). The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Read the original here:
Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook

Recommendation and review posted by G. Smith

SAN DIEGO, CA--(Marketwire - Nov 7, 2012) - COARE Biotechnology (COARE) and ChemDiv, Inc. (ChemDiv) announced today the formation of a strategic alliance that will offer a fully integrated gene-to-clinic services aimed at development of therapeutic agents that selectively affect cancer stem cells (CSC).

Under terms of this agreement, COARE contributes its pioneering research on the role of Doublecortin-like Kinase 1 (DCLK1) in proliferation and differentiation of CSC including relevant screening reagents and know-how. ChemDiv provides chemistry and biology expertise, including i) small molecule screening libraries, Medicinal Chemistry support, ii) assay adaptation, development and implementation, iii) in vivo testing and iv) advanced preclinical services including DMPK/tox. Dr. Ilya Okun, VP of Biology and CTO at ChemDiv, said: "COARE scientists, have identified a novel enzyme, DCLK1, which plays a key role in development of many solid tumors. This kinase is a promising and tractable target for the discovery of novel specific anti-cancer therapies. I am very excited that the collaboration between ChemDiv and COARE on this program will allow for discovery of new ways to treat a panel of cancers, for which there currently is no effective medicine."

Dr. Courtney W. Houchen, Chief Medical Adviser and cofounder, said, "We are excited at this partnership opportunity and the fact that this collaboration with ChemDiv will bring to the doorstep of both pharmaceutical and biotechnology companies worldwide, our research, expertise and our proprietary assays to help discover small molecules that target, and potentially eradicates or functionally inactivates the most resistant subpopulation of most tumors, the cancer stem cells."

About ChemDiv ChemDiv, Inc. is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world. We engage pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes. More information about ChemDiv is available at http://www.chemdiv.com.

About COARE COARE Biotechnology is a research driven biotechnology company dedicated to developing novel anti-cancer therapeutic agents designed to treat solid tumor cancers headquartered in Oklahoma City, OK USA. Our agents are directed against DCLK1, a novel molecular target whose mechanism of action involves multi-pathway, multi-functional cancer inhibition. Recently completed research has shown that this stem cell related protein plays a functional role and is increased in human pancreatic cancer. This protein works to turn off natural tumor suppressors and turns on cancer-causing genes. We are determined to eradicate solid tumor cancers in our lifetime. For additional information about us go to http://www.coarebiotechnology.com

Read more from the original source:
Coare Biotechnology and ChemDiv Establish Co-Marketing and Service Collaboration

Recommendation and review posted by G. Smith

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 2:00 p.m. EST on Wednesday, November 14, at the Lazard Capital Markets 9th Annual Healthcare Conference in New York City.

A live webcast will be available on the Companys website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

View post:
Puma Biotechnology to Present at Lazard Healthcare Conference

Recommendation and review posted by G. Smith